Cipla Ltd banner

Cipla Ltd
BSE:500087

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
BSE:500087
Watchlist
Price: 1 243.9 INR 2.02% Market Closed
Market Cap: ₹1T

Multiples-Based Value

The Multiples-Based Value of one CIPLA stock under the Base Case scenario is 1 640.47 INR. Compared to the current market price of 1 243.9 INR, Cipla Ltd is Undervalued by 24%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CIPLA Multiples-Based Value
Base Case
1 640.47 INR
Undervaluation 24%
Multiples-Based Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

CIPLA Competitors Multiples
Cipla Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Cipla Ltd
BSE:500087
1T INR 3.5 22 14 16.9
US
Eli Lilly and Co
NYSE:LLY
865.7B USD 13.1 41.3 27.9 29.8
US
Johnson & Johnson
NYSE:JNJ
577.7B USD 6.2 21.6 15 18.5
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.3 11.4 12.9
US
Merck & Co Inc
NYSE:MRK
295.4B USD 4.6 16.2 10 12.2
UK
AstraZeneca PLC
LSE:AZN
218.1B GBP 4.9 28.1 15.6 22
CH
Novartis AG
SIX:NOVN
229.5B CHF 5.2 21.1 13.1 16.8
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.5 10.5 7.8 9.1
US
Pfizer Inc
NYSE:PFE
155.1B USD 2.5 20.2 7.8 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.6B USD 2.5 16.9 7.1 8.8
P/E Multiple
Earnings Growth PEG
IN
Cipla Ltd
BSE:500087
Average P/E: 21.7
22
2%
11
US
Eli Lilly and Co
NYSE:LLY
41.3
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.2
14%
1.2
UK
AstraZeneca PLC
LSE:AZN
28.1
26%
1.1
CH
Novartis AG
SIX:NOVN
21.1
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
US
Pfizer Inc
NYSE:PFE
20.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Cipla Ltd
BSE:500087
Average EV/EBITDA: 45.9
14
2%
7
US
Eli Lilly and Co
NYSE:LLY
27.9
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10
3%
3.3
UK
AstraZeneca PLC
LSE:AZN
15.6
13%
1.2
CH
Novartis AG
SIX:NOVN
13.1
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.8
1%
7.8
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Cipla Ltd
BSE:500087
Average EV/EBIT: 99.9
16.9
1%
16.9
US
Eli Lilly and Co
NYSE:LLY
29.8
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.5
6%
3.1
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.1
US
Merck & Co Inc
NYSE:MRK
12.2
6%
2
UK
AstraZeneca PLC
LSE:AZN
22
21%
1
CH
Novartis AG
SIX:NOVN
16.8
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett